2022 AHA/ACC/HFSA 心力衰竭管理指南执行摘要
指南依据当代证据更新既往推荐并在有数据支持时新增推荐,对具有高质量经济学分析的治疗给出价值声明。
要点
- 本指南替代 2013 年心衰指南及 2017 年聚焦更新,提供以患者为中心的推荐。
- 推荐基于当代证据更新,并在有发表数据支持时新增推荐。
- 对具有高质量经济学分析的部分治疗给出价值声明。
核心结论
- 2022 年指南基于当代证据为心衰患者的预防、诊断和管理提供以患者为中心的建议,旨在改善医疗质量并与患者利益保持一致。
研究设计与样本
- 检索涵盖 MEDLINE(PubMed)、EMBASE、Cochrane Collaboration、Agency for Healthcare Research and Quality 等数据库中发表的英文人体研究、综述及其他证据。
主要发现
- 心力衰竭仍是全球致病和致死的主要原因之一。
- 既往心衰指南的许多推荐已根据新证据更新,并在有发表数据支持时新增了推荐。
关键数值与推荐
- 对某些具有高质量已发表经济学分析的治疗提供价值声明。
临床怎么用
- 临床医生可依据本指南的循证推荐对心衰患者进行预防、诊断和管理,以改善医疗质量并与患者利益保持一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. METHODS: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.
引用
- Heidenreich, Bozkurt, Aguilar, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022. PMID: 35363500. doi:10.1161/CIR.0000000000001062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。